IGC · IGC Pharma, Inc.
$0.24
-0.02 (-7.34%)
At close · Jul 29
Going-concern doubt
— cleared May 15, 2026
The latest filing states the doubt was alleviated.
“raise substantial doubt about its ability to continue as a going concern. The Company is currently in the clinical trial stage and has not yet achieved profitability. The Company expects to continue to incur significant operating and net losses, as well as negative cash flow from operations, in the near future.”View the 10-Q filed May 15, 2026
Market Cap
$25.92M
Shares
100.09M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.24
Open$0.26
Day$0.24–0.26
52W$0.24–0.50
Avg vol 30d454K
Short int389K · 0.4% float · 1.0d
Short vol42%
DataJan 2020–Jul 2026
Filing10-Q · May 15
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−21%
below
Price vs 50-day avg
−13%
below
RSI (14)
27
oversold
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−11%
trailing
6-month return
−8%
trailing
YTD return
−14%
this year
Relative strength
−14%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Distributing
8 of 35 funds reported for Jun 30 · net -8.5K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.39% of float · ▼ -19.8% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
35 holders — near 3-yr high, broad support
Squeeze score
30
low risk · 0–100
Fundamentals
Revenue growth
−6%
Y/Y
Gross margin
49%
contracting
EPS growth
+59%
Y/Y
Free cash flow
$-4.9M
Balance sheet
$769.0K
net cash
Quant / Vol
risk profile
Volatility
55%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
5.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−21%
Bearish
Price vs 50-day avg
−13%
Bearish
RSI (14)
27
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Distributing
8 of 35 funds reported for Jun 30 · net -8.5K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.39% of float · ▼ -19.8% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
35 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $0
Now $0 · 2%
52-wk high $1
vs 200-day avg -21%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IGC
this stock
IGC Pharma, Inc.
|
$25.92M | -14.3% | +39.5% | — | 0.4% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +7.7% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.67B | +6.6% | +46.2% | 28.7 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.91B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IGC | -11.1% | -11.1% | -7.7% | -11.1% | -14.3% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | -8.7% | -8.8% | -14.0% | -8.8% | -21.3% |